Cancer

Government of Canada announces first-of-its-kind biomanufacturing facility in British Columbia

Opening of cutting-edge biomanufacturing facility creates more than 1,000 Canadian jobs, boosting the domestic life sciences sector BURNABY, BC, July…

1 year ago

Cosmos Health’s Cana Secures Contract Manufacturing Agreement with Australia’s Humacology for up to 500,000 CBD Units Annually

CHICAGO, IL / ACCESSWIRE / July 9, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

1 year ago

Lunit Appoints Volpara CEO Teri Thomas as Chief Business Officer of Cancer Screening Group

Seasoned medical technology leader to drive global expansion and innovation in AI-driven cancer screeningSEOUL, South Korea, July 9, 2024 /PRNewswire/…

1 year ago

Pascal Piedbois, MD, PhD joins One2Treat as Chief Medical Officer to advance patient-centric innovation in clinical trial design and market access

One2Treat reflects patient priorities in a single multi-facet treatment assessment, reducing trial sample size and accelerating patient access to new…

1 year ago

Ludwig Enterprises Files Provisional Patent on mRNA Genetic Screening Signals in Breast, Colon and Bladder Cancer

SPARKS, NV / ACCESSWIRE / July 9, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG), a USA based biotechnology company is…

1 year ago

Microbot Medical Continues to Ramp Up Patient Enrollment in its Pivotal Human Clinical Trial

Baptist Hospital of Miami is the second site to perform clinical procedures as part of the Company’s Pivotal Human Clinical…

1 year ago

American Shared Hospital Services Announces Signing of Joint Venture Agreement for Gamma Knife Facility in Guadalajara, Mexico

JV will Establish Company’s 4th International CenterSAN FRANCISCO, July 09, 2024 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS)…

1 year ago

Achieve Life Sciences to Present at JonesHealthcare Seaside Summit 2024

SEATTLE and VANCOUVER, British Columbia, July 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical…

1 year ago

Elevar Therapeutics Reports Plans for Near-Term Resubmission of NDA for First-Line Treatment Option for Unresectable Hepatocellular Carcinoma Following Type A FDA Meeting

FDA confirmed resubmission can occur without delayFDA confirmed additional GMP and/or BIMO inspections may occur after resubmissionElevar plans to resubmit…

1 year ago